Feline Mast Cell Tumor

Feline mast cell tumor (MCT), also known as mastocytoma, is a neoplasm arising from mast cells — tissue-resident immune cells packed with granules containing vasoactive mediators such as histamine, heparin, and proteases. It is the second most frequent malignant cutaneous tumor in cats, and a leading cause of splenic and gastrointestinal neoplasia in the species [1]. MCTs in cats are biologically distinct from their canine counterparts, occurring in three principal anatomical forms: cutaneous, visceral (splenic), and gastrointestinal, each with differing clinical behavior and prognosis [1][2]. The systemic release of mast cell mediators can cause paraneoplastic signs that complicate management and significantly affect patient quality of life.

The precise etiology of feline MCT remains incompletely understood, but molecular, genetic, and anatomical factors have been identified:

Molecular Pathogenesis — c-KIT Mutations: The proto-oncogene c-KIT (CD117) encodes a transmembrane receptor tyrosine kinase critical for mast cell survival, proliferation, and differentiation. Gain-of-function mutations in c-KIT lead to constitutive, ligand-independent receptor activation, driving uncontrolled mast cell proliferation. In cats, c-KIT mutations have been documented in both cutaneous and splenic MCTs; importantly, intratumoral heterogeneity of c-KIT mutations has been demonstrated within individual tumors, with different mutation variants co-existing in the same splenic MCT [5]. This heterogeneity has direct clinical implications: it can underlie acquired resistance to targeted therapies such as toceranib, as subclones harboring alternative mutations may survive and repopulate the tumor [5]. Immunohistochemically, KIT protein expression is detectable in 69% of cutaneous MCTs, 35% of splenic MCTs, and 33% of gastrointestinal MCTs [8].

Mast Cell Mediator Release: Mast cell granules contain histamine, heparin, tryptase, chymase, and various cytokines. Tumor-associated degranulation — whether spontaneous or triggered by physical manipulation — releases these mediators systemically. Histamine stimulates gastric parietal cell H₂ receptors, causing hypersecretion of hydrochloric acid and subsequent gastroduodenal ulceration. Heparin release disrupts the coagulation cascade, contributing to hemorrhage risk [1][8].

Anatomical Predispositions:

• ·Cutaneous MCTs occur predominantly on the head and neck in cats, with Siamese cats historically reported to have a higher incidence of histiocytic/atypical cutaneous MCT variants.
• ·Splenic MCTs frequently arise as a primary visceral tumor and represent the most common splenic malignancy in cats, accounting for 42% of splenic neoplasms in one referral population [4].
• ·Gastrointestinal MCTs can co-occur synchronously with small cell lymphoma; a distinct clinicopathological entity of synchronous GI small cell lymphoma and GI MCT has been characterized, with tumors classified as either distinct (each cell type forming separate populations) or mixed (collision or composite patterns) [7].

Cell Biology of Mast Cell Death: At a cellular level, mast cells are uniquely susceptible to osmotic lysis; experimental work confirmed that exposure to deionized water causes progressive swelling, degranulation, and membrane rupture in mastocytoma cells, with 90% cell death within 2 minutes in vitro [6]. This osmotic vulnerability has been explored as a potential adjunct local treatment approach.

Diagnosis of feline MCT requires integration of physical examination findings, cytology, histopathology, and staging diagnostics.

Cytology (Fine-Needle Aspirate / FNA): FNA of the mass or enlarged lymph nodes typically reveals round cells with abundant cytoplasmic metachromatic granules (staining purple-red with Diff-Quik or toluidine blue). Cytology is the first-line diagnostic tool and is highly reliable for MCT identification. Eosinophils are often present in the background.

Histopathology and Grading: Excisional or incisional biopsy provides definitive diagnosis and is essential for histological grading. Feline cutaneous MCTs have historically been classified as compact (well-differentiated) or diffuse (poorly differentiated), with the diffuse form carrying a worse prognosis [1]. Mitotic index, degree of granularity, and infiltrative pattern are assessed. Unlike canine MCTs, a universally validated multi-tiered grading system (e.g., Patnaik or Kiupel) has not been formally established for feline cutaneous MCT, though grading remains clinically important.

Immunohistochemistry: KIT (CD117) expression can be evaluated immunohistochemically to assess receptor overexpression or aberrant localization. Histamine and serotonin immunoreactivity can also be evaluated — GI MCTs show the highest histamine immunoreactivity (53%), followed by cutaneous (28%) and splenic (18%) forms [8]. KIT positivity is highest in cutaneous MCTs (69%) [8].

c-KIT Mutation Testing: Molecular testing for c-KIT mutations (particularly exon 8 and exon 11) informs eligibility for tyrosine kinase inhibitor (TKI) therapy. Intratumoral heterogeneity means that a single biopsy sample may not capture all mutation variants present, potentially affecting treatment planning [5].

Staging and Imaging: Full staging is recommended for all confirmed MCT cases and includes:

• ·Abdominal ultrasonography: Essential for evaluating spleen, liver, mesenteric lymph nodes, and GI tract. Splenic MCT typically appears as diffuse or nodular hypoechoic parenchymal changes.
• ·Thoracic radiography: To detect pulmonary metastasis or mediastinal involvement.
• ·Bone marrow aspirate/biopsy: Indicated for systemic (mast cell leukemia) staging, particularly when peripheral blood mast cells are identified.
• ·Regional lymph node aspirate: To detect locoregional spread.

Relevant Laboratory Indicators:

Peripheral Blood Smear: Mast cells in circulation are abnormal and may indicate systemic mastocytosis or mast cell leukemia.

Gastroscopy / Colonoscopy: For GI MCT, endoscopy with biopsy is valuable. Special consideration: endoscopic biopsies may be insufficient depth to capture infiltrative mast cell infiltrates in the submucosa; full-thickness surgical biopsy is sometimes preferred.

Treatment strategy depends on anatomical location, stage, and the presence of metastatic or systemic disease.

1. Surgery

Cutaneous MCT: Surgical excision is the treatment of choice for localized cutaneous MCTs. Wide excision margins are recommended; the current surgical guidance supports excision with adequate lateral and deep margins, though the exact margin width continues to be refined in veterinary surgical oncology literature [3]. Complete excision with histologically confirmed clean margins is associated with favorable outcomes. Pre-operative antihistamine administration (H₁ and H₂ blockers) is strongly recommended to reduce the risk of intraoperative degranulation crises [1].

Splenic MCT: Splenectomy is the cornerstone of treatment for splenic MCT. In a multi-institutional retrospective study of 64 cats, splenectomy alone achieved a median tumor-specific survival (MTSS) of 856 days, and splenectomy combined with chemotherapy achieved an MTSS of 853 days [2]. Pre- and peri-operative antihistamine prophylaxis is essential to prevent histamine-mediated hypotension during surgical handling of the spleen.

Gastrointestinal MCT: Surgical resection of discrete GI MCT masses is appropriate when feasible, though diffuse infiltrative disease limits surgical curative intent.

2. Chemotherapy

Indications: Incompletely excised tumors, metastatic disease, visceral/systemic MCT, or cases not amenable to surgery.

• ·Lomustine (CCNU): A nitrosourea alkylating agent; considered a primary chemotherapy agent for feline MCT. Myelosuppression (especially neutropenia and thrombocytopenia) is the principal dose-limiting toxicity; CBC monitoring is mandatory.
• ·Vinblastine: Used in combination protocols or as an alternative agent.
• ·Prednisolone/Glucocorticoids: Commonly incorporated into protocols for their anti-inflammatory, anti-proliferative, and palliative effects; also help reduce mast cell mediator-associated GI signs.
• ·Chlorambucil: May be used in combination, particularly for GI MCT.

In the splenic MCT study, cats receiving chemotherapy alone (without splenectomy) achieved a markedly shorter MTSS of only 244 days, highlighting the primary role of surgery [2].

3. Targeted Therapy — Tyrosine Kinase Inhibitors (TKIs)

• ·Toceranib phosphate (Palladia): A receptor TKI with activity against KIT, VEGFR, and PDGFR. Used in cats with c-KIT mutations or KIT-overexpressing MCTs. Response rates in feline MCT have been reported, though acquired resistance due to intratumoral c-KIT mutation heterogeneity can limit durability of response [5].
• ·Masitinib: Another TKI with KIT inhibitory activity; used in some feline MCT cases.
• ·Monitoring for TKI-related toxicities (GI signs, myelosuppression, proteinuria) is important during therapy.

4. Radiation Therapy

Radiation therapy may be considered for incompletely excised cutaneous MCTs where re-excision is not feasible, or as adjuvant treatment. It is less commonly employed for visceral MCT.

5. Local / Investigational Treatments

Intralesional deionized water injection has been explored as a local treatment approach based on the demonstrated osmotic sensitivity of mast cells, with 90% in vitro cell death within 2 minutes of exposure [6]. This approach may be considered in cases where conventional surgery is impractical, though clinical evidence remains limited.

6. Supportive and Symptomatic Care

• ·H₁ antihistamines (e.g., diphenhydramine, chlorphenamine): Control pruritus and reduce systemic histamine effects.
• ·H₂ antihistamines / Proton pump inhibitors (e.g., famotidine, omeprazole): Prevent and treat histamine-induced gastric ulceration — critically important in all MCT cases.
• ·Sucralfate: Gastric mucosal protectant for active ulceration.
• ·Anti-emetics: Maropitant for vomiting control.
• ·Nutritional support: Enteral feeding for cachectic patients.
• ·Blood transfusion: For severe anemia secondary to GI hemorrhage or myelosuppression.

Prognosis in feline MCT varies substantially by anatomical location, disease extent, and treatment modality:

Cutaneous MCT:

• ·Cutaneous MCTs in cats are generally considered less aggressive than in dogs, and many are cured by complete surgical excision [1].
• ·Compact (well-differentiated) cutaneous MCTs carry an excellent prognosis with surgery; diffuse (poorly differentiated) subtypes behave more aggressively with higher recurrence and metastatic rates [1].
• ·Multiple cutaneous MCTs may indicate systemic disease and warrant full staging.

Splenic MCT:

• ·Splenic MCT treated with splenectomy alone: Median tumor-specific survival (MTSS) = 856 days [2]
• ·Splenic MCT treated with splenectomy + chemotherapy: MTSS = 853 days [2]
• ·Splenic MCT treated with chemotherapy alone: MTSS = 244 days [2]
• ·Splenic MCT with supportive care only: MTSS = 365 days [2]
• ·These data clearly demonstrate that splenectomy is the most impactful intervention; the addition of chemotherapy to splenectomy did not significantly extend survival in this study [2].
• ·Splenectomy is also commonly performed for diagnostic and therapeutic purposes in cats with splenic masses; 81% of cats undergoing splenectomy in one UK referral study were found to have splenic neoplasia, with MCT being the most common diagnosis at 42% [4].

Gastrointestinal MCT:

• ·GI MCTs tend to carry a guarded to poor prognosis, particularly when diffuse or associated with systemic involvement.
• ·Synchronous GI MCT with small cell lymphoma represents a complex, emerging clinical entity where classification and prognosis continue to be refined [7].

Prognostic Factors Associated with Poorer Outcome:

• ·Diffuse/poorly differentiated histological subtype
• ·High mitotic index
• ·Metastatic disease at diagnosis (lymph node, liver, bone marrow)
• ·GI ulceration and hemorrhage
• ·Mast cell leukemia (circulating mast cells)
• ·Intratumoral c-KIT mutation heterogeneity leading to TKI resistance [5]
• ·Failure to achieve complete surgical margins

Recurrence: Tumor recurrence (as documented in one feline splenic MCT case) can occur rapidly — within 117 days of complete remission with toceranib therapy — and is associated with the emergence of resistant subclones due to intratumoral mutation heterogeneity [5].

There are currently no vaccines or proven preventive measures for feline MCT. The following general recommendations are relevant:

• ·Routine veterinary examinations: Early detection of cutaneous nodules or abdominal masses significantly improves treatment outcomes. Monthly owner skin checks and biannual veterinary physical examinations — including abdominal palpation — are recommended for all cats, particularly those over 8 years of age.
• ·Breed awareness: Siamese cats may have an increased predisposition to certain MCT variants; owners of this breed should maintain heightened vigilance for skin and gastrointestinal signs.
• ·Prompt evaluation of skin masses: Any new or changing skin nodule in a cat should be evaluated cytologically rather than observed over extended periods, as MCT can mimic benign lesions clinically.
• ·Monitoring cats with a prior MCT diagnosis: Given the possibility of multiple synchronous tumors (e.g., concurrent GI and cutaneous MCT) [7], and the risk of recurrence [5], cats with a confirmed MCT diagnosis should undergo regular full-body examinations and abdominal imaging at follow-up intervals determined by their oncologist.
• ·Avoid unnecessary manipulation of suspected MCTs: Physical degranulation of suspected mast cell masses prior to pre-medication can precipitate a systemic histamine crisis; practitioners should pre-medicate with H₁/H₂ blockers before biopsy or surgical procedures.
• ·No dietary, environmental, or genetic screening interventions have been validated to prevent the development of feline MCT in the current peer-reviewed literature.